Fiddian A P
Scand J Infect Dis Suppl. 1985;47:116-20.
In view of the enormous public health concern about chronic hepatitis B, the lack of available therapies and because no good in vitro or in vivo screening tests exist new antiviral agents have been tried empirically in this disease. Several agents, including acyclovir, have now been studied with some apparent success though none have yet been subjected to adequately controlled trials. Acyclovir has the advantage of being better tolerated but to date has been limited by having to be given intravenously. New prodrugs of acyclovir may facilitate its oral administration but the ultimate role of these in the management of chronic hepatitis B, either as single or combined therapy, remains to be determined.
鉴于对慢性乙型肝炎存在巨大的公共卫生担忧、缺乏可用的治疗方法且不存在良好的体外或体内筛选试验，新型抗病毒药物已在该疾病中进行了经验性试验。包括阿昔洛韦在内的几种药物目前已得到研究，虽未进行充分对照试验，但有一些明显的效果。阿昔洛韦具有耐受性较好的优点，但迄今为止，由于必须静脉给药而受到限制。阿昔洛韦的新前体药物可能有助于口服给药，但其在慢性乙型肝炎管理中作为单一疗法或联合疗法的最终作用仍有待确定。
